Published in final edited form as:

Biochemistry. 2012 January 10; 51(1): 307–315. doi:10.1021/bi201288x.

Dihydroxybenzoic Acid Isomers Differentially Dissociate Soluble Biotinyl-A β (1–42) Oligomers

Harry LeVine III*,

Department of Cellular and Molecular Biochemistry, Center on Aging, Center for Structural Biology, University of Kentucky

Levi Lampe,

Department of Cellular and Molecular Biochemistry, Center on Aging, Center for Structural Biology, University of Kentucky

Lina Abdelmoti, and

Department of Cellular and Molecular Biochemistry, Center on Aging, Center for Structural Biology, University of Kentucky

Corinne E. Augelli-Szafran

[†]Center for Neurologic Diseases, Harvard Medical School, Brigham and Women's Hospital, Boston, MA 02115

Abstract

Polyphenolic compounds including a number of natural products such as resveratrol, curcumin, catechin derivatives, and nordihydroguaiaretic acid have effects on the assembly of A β fibrils and oligomers as well as on fibril morphology. Based on a lead structure obtained from a screen of a small molecule diversity library, simple benzoic acid derivatives distinguished by the number and position of hydroxyls on the aromatic ring displayed different abilities to dissociate pre-formed biotinyl-A β (1–42) oligomers. The 2, 3-, 2, 5-, and 3, 4- dihydroxybenzoic acid (DHBA) isomers were active oligomer dissociators. The remaining DHBA isomers and the monohydroxy and unsubstituted benzoic acids were inactive and did not compete with the active compounds to block oligomer dissociation. None of the compounds blocked oligomer assembly, indicating that they do not interact with monomeric A β to shift the oligomer-monomer equilibrium. Dissociating activity was not associated with quinone redox cycling capacity of the compounds. Gallic acid (3, 4, 5-trihydroxybenzoic acid) stabilized biotinyl-A β (1–42) oligomers against intrinsic dissociation and blocked the effects of the active dissociators, independent of the concentration of dissociator.

A model for the mechanism of action of the DHBA dissociators proposes that these compounds destabilize oligomer structure promoting progressive monomer dissociation rather than fissioning oligomers into smaller, but still macromolecular species. Gallic acid blocks dissociation by stabilizing oligomers against this process.

*CORRESPONDING AUTHOR: Harry LeVine, III, hlevine@email.uky.edu, PHONE: 859-257-1412 X224, FAX: 859-323-2866, ADDRESS: 800 S. Limestone Street, Lexington, KY 40536-0230.

Assembly of A β peptides and other amyloidogenic peptides and proteins into soluble non-fibrillar structures produces a species highly toxic to cells (1–4). A β oligomers are proposed as a primary etiologic agent in Alzheimer's disease initiating a cascade of events by binding to synapses, dysregulating multiple aspects of synaptic function and disrupting long-term-potential which is postulated to form the basis of learning and memory (5–8). Efforts at ameliorating toxic A β effects by inhibiting assembly of amyloid fibrils with small molecules have shifted to the assembly of the more diffusible and acutely toxic soluble A β oligomers. Thus far, literature reports of screens for oligomer assembly inhibitors have been limited (9–14). An adaptation of our previously reported assay system for screening chemical libraries for A β oligomer assembly inhibitors using a biotinylated A β (1–42) peptide, Neutravidin-coated ELISA plates for capture, and Streptavidin-HRP detection in an oligomer-specific configuration (15, 16) readily measures dissociation of preformed bio42 oligomers.

A small molecule structural diversity compound library (ApexScreen 5040 from TimTec) was screened for structures that 1) blocked soluble A β peptide oligomer assembly from synthetic biotinyl-A β (1–42) (bio42) monomers, or 2) dissociated preformed bio42 oligomers. In both cases, a NeutravidinTM (NA)-coated and blocked 96-well ELISA plate was used to capture the N-terminally labeled bio42, followed by streptavidin-horseradish peroxidase to selectively detect multimeric bio42 (15). Several structural classes of compounds with the ability to inhibit bio42 oligomer assembly were defined. The properties of one class, a substituted 8-hydroxyquinoline series of assembly inhibitor compounds, have been described (16). Here we describe the oligomer dissociating activity of a series of hydroxybenzoic acid isomers from commercial sources selected on the basis of an active dihydroxybenzoic acid (DHBA) derivative from the screen. These simple structures differ in the number and position of phenolic hydroxyls which profoundly affected their potency and kinetics of dissociation. None of these compounds block bio42 oligomer assembly, indicating that they likely target a different aspect of oligomer structure than assembly inhibitors such as the 8-hydroxyquinolines (16).

Interestingly, the most potent and rapidly acting compound against oligomers, 2, 5-dihydroxybenzoic acid (gentisic acid), had no effect on preformed A β (1–40) amyloid fibrils, while 3, 4, 5-trihydroxybenzoic acid (gallic acid) rapidly decreased fibril-dependent Thioflavine T fluorescence without competing for Thioflavine T binding. Gallic acid did not dissociate but instead stabilized preformed bio42 soluble oligomers against both intrinsic dissociation and DHBA compound-induced dissociation.

Superdex 75 size exclusion chromatography and glutaraldehyde crosslinking analysis of the bio42 oligomer dissociation reaction failed to detect intermediate size oligomeric bio42 species less than the 70–100 kDa exclusion limit of Superdex 75. These observations support a model in which the DHBA dissociators bind to bio42 oligomers and allow individual peptide monomers to dissociate rather than fission oligomers into smaller assemblies.

Materials and Methods

The benzoic acid derivatives, resveratrol, nordihydroguaiaretic acid, Tween 20 (ultrapure), Triton X-100, 1, 1, 1, 3, 3, 3 - hexafluoro-2-propanol (HFIP), BSA (Fraction V), PMSF, trifluoroacetic acid, DMSO, tetramethylbenzidine (free base), N, N-dimethylacetamide, Sephadex G-75 (medium), 70% glutaraldehyde (Fluka, EM grade) and 30% w/w H₂O₂ were purchased from Sigma-Aldrich (St. Louis, MO). Nitroblue tetrazolium was from MP Biomedicals, curcumin from Cayman Chemicals (Ann Arbor, MI), and (–)-epigallocatechingallate (EGCG) from Enzo Life Sciences (Plymouth Meeting, PA). N- α -biotinyl-A β (1–42) (bio42) (cat# 23523 lot numbers 20240, 29672, and 56610) was purchased from Anaspec (San Jose, CA). Monoclonal A β (un-modified and biotinylated) antibodies to the human sequence A β -peptide, 6E10 (a.a. 3–8) and 4G8 (a.a. 17–24) were purchased from Covance Labs (Princeton, NJ). HRP-labeled streptavidin and HRP-goat anti-mouse secondary antibody were purchased from Rockland, Inc. (Gilbertsville, PA). NeutrAvidin™ was obtained from Pierce (Rockford, IL). High Binding ELISA plates were obtained from Costar (product number 9018) (Cambridge, MA). 12% NuPAGE gels and Mes SDS running buffer were from Invitrogen. [Life Technologies] (Grand Island, NY). Nitrocellulose (0.2 μ m pore size) was obtained from BioRad (Hercules, CA).

Preparation of preformed biotinyl-A β (1–42) (bio42) oligomers

An aliquot of N-terminal biotinyl-A β (1–42) peptide stored at –75 °C in HFIP solution was disaggregated as described (16) to convert any assembly intermediates into monomeric peptide. Briefly, the HFIP was removed from the desired amount of peptide in a polypropylene tube with a gentle stream of inert gas, dissolved in a minimal volume of neat trifluoroacetic acid (TFA), incubated at room temperature for ten minutes, and then removing the TFA with an inert gas stream. Twenty-five μ l of HFIP was added to redissolve the peptide film and was then removed along with any residual TFA with an inert gas stream. DMSO was added to the film to produce an 8 μ g bio42/ml stock solution. After ten minutes the disaggregated peptide in DMSO was diluted 50-fold into oligomer-forming buffer (OFB, 20 mM sodium phosphate, 145 mM NaCl, pH 7.5) in a polypropylene container to 0.16 μ g/ml (33.7 nM expressed as monomeric peptide) and mixed thoroughly. After one hour at room temperature an equal volume of OFB containing 0.6% v/v Tween 20 was added to stop the assembly reaction and stabilize the oligomers. This 16.8 nM mixture of oligomeric and monomeric bio42 peptide (bio42 oligomers) was either used immediately or frozen in aliquots at –75 °C in polypropylene tubes for storage up to six months. Oligomers prepared by this method are >70 kDa, and their 100 – 600 kDa size distribution by size exclusion chromatography (17) is similar to that of A β oligomers from AD brain(18).

Dissociation of preformed bio42 oligomers

Twenty-five microliters of 16.8 nM preformed bio42 oligomers in OFB + 0.3% Tween 20 were placed in the bottom of wells in a polypropylene (wide well) 96-well plate (0.5 ml well capacity (Fisher 12565502) and 125 μ l of OFB containing the desired concentration of compound and 1 % v/v DMSO. The plate was sealed with a plastic sheet (Nunc 236366) and

incubated at room temperature with shaking at 150 rpm for 16–18 hours. Tween 20 was included in the incubation to prevent oligomer reformation and to improve recovery at the low final peptide concentration of 2.8 nM. The presence of Tween 20 is not required for dissociation by compounds but significantly improves the reproducibility of the assay.

After incubation, the plate was centrifuged at 1,000 ×g for 10 min at room temperature to collect condensation from the plastic seal area covering the wells. The amount of bio42 oligomers remaining was measured by transferring 100 µl from each well to an NA-coated (50 ng/well) well of an ELISA plate, incubating with shaking for 2 hr and detecting with SA-HRP (15).

Time course of bio42 oligomer dissociation

A dose-response of 2, 3-, 2, 5-, and 3, 4-DHBA compounds was prepared in quadruplicate in one plate with preformed 2.8 nM bio42 oligomers, using one plate for each time point. At each time point (0, 2, 4, 6, 8, 12, and 24 h), a plate was frozen at –20 °C. After the last time point was collected and frozen, all plates were thawed and the oligomer content measured. Control experiments indicated that the freezing and storage did not affect the oligomer signal.

Superdex 75 size exclusion chromatography

A time course (0, 2, 5, 8 hours) of dissociation of preformed bio42 oligomers (30 nM total Aβ) was carried out in OFB + 0.1% Tween 20 in the presence of 5 µM 2, 5-dihydroxybenzoic acid or 1% DMSO as a solvent vehicle control at room temperature in 0.65 ml low binding 0.65 ml) Eppendorf tubes (250 µl per tube). At each time point a 25 µl aliquot was removed for glutaraldehyde-crosslinking and the remaining sample was frozen at –20 °C. After thawing at room temperature, 200 µl was injected onto a 10/30 HR Superdex 75 column equilibrated with OFB + 0.1% Tween 20 operating at 0.5 ml/min. Fractions (0.2 ml) were collected in a 96-well polypropylene plate (Costar 3365), frozen at –20 °C for analysis by ELISA. All chromatography runs were on the same day.

Aliquots of column fractions were applied to NA-coated plates (50 ng/well) blocked with OFB + 0.1% Tween 20, incubated for 2 hours, and washed. The plates were sequentially incubated for 1 hour with 50 µl/well of 0.5 µg/ml 4G8 monoclonal antibody in OFB + 0.1 % Tween 20 + 2 mg/ml BSA (Calbiochem), washed and then incubated for 1 hour with 50 µl 1:10,000 goat-anti-mouse IgG-HRP (Rockland). After washing, HRP activity was detected with tetramethylbenzidine (15). All ELISAs were performed on the same day.

Glutaraldehyde crosslinking of bio42 oligomers

Twenty-five microliter samples containing 30 nM bio42 were incubated for 5 minutes at room temperature in 0.65 ml low binding 0.65 ml) Eppendorf tubes with 0.0125% glutaraldehyde (final concentration), quenched by the addition of Tris-HCl, pH 7.5 to 40 mM, and NuPAGE sample buffer (4×) added. The samples were heated for 5 minutes at 90 °C and then either frozen or separated immediately on 12% NuPAGE gels in Mes running buffer. The gels were transferred to 0.2 µm pore size nitrocellulose for 70 minutes at 30 V constant voltage in a Novex blotter in NuPAGE transfer buffer + 10% methanol. The blots

were boiled in OFB for 5 minutes then blocked in 3% w/v Blotto (Santa Cruz) in OFB. Detection was with either Streptavidin conjugated to an 800 nm fluor or 4G8/goat anti-mouse-conjugated to an 800 nm fluor. Quantification was with an Odyssey imager (LI-COR Biosciences, Lincoln, NE).

Proteolytic sensitivity of bio42 oligomers

Twenty-five microliters of 16.8 nM preformed bio42 oligomers were placed in the bottom of wells in a polypropylene 96-well plate (0.5 ml well capacity) and 125 μ l of OFB containing 10 μ M compound in OFB + 0.1% Tween 20 added for 30 min at room temperature. Fifteen μ l of a 2-fold dilution series of trypsin in OFB + 0.1% Tween 20 were added to each well followed by shaking at 150 rpm for 30 additional minutes at room temperature. One microliter of freshly dissolved 20 mg/ml phenylmethylsulfonyl fluoride in DMSO was added to each well to inhibit further proteolysis at a 120 μ g/ml final concentration. One hundred μ l of the reaction in each well was transferred to a NA-coated and blocked ELISA plate and incubated with shaking for two hours. The oligomer signal remaining was detected with SA-HRP as for the dissociation reaction.

Redox cycling of quinone precursors

The redox cycling capacity of compounds was measured with a colorimetric assay system with alkaline glycine as an electron donor adapted from Flückiger *et al.* (19). Compounds were diluted from stock solutions in DMSO to give 0.3125 to 20 pmoles per microliter in distilled water and a residual 1% v/v of DMSO. Twenty-five microliters of each dilution of compound were incubated in a well of a clear polystyrene 96-well round bottom plate (Costar 3798) with 200 μ l of a reaction mixture consisting of 10 mM sodium tetraborate, 0.7 mg/ml borohydride-treated and dialyzed BSA, 0.2 mM nitroblue tetrazolium chloride (NBT) in 2M potassium glycinate buffer, pH 10 for one hour in the dark at room temperature. The BSA-stabilized NBT formazan complex was measured at 530 nm in a Biotec Synergy HT plate reader.

Results

2, 5-dihydroxybenzoic acid dose-dependently reduced the amount of oligomeric bio42 detected by the single-site assay format which produces a signal only when multiple biotins are present in the multimeric species captured by the biotin-binding protein Neutravidin (15). Monomeric protein is not detected by the Streptavidin-HRP because the single biotin in the biotinyl-A β (1–42) monomer is captured by the Neutravidin on the plate. The biotin/avidin system is often used in screening of chemical compounds because of the high affinity of the interaction and because only biotin-related compounds interfere significantly. Verification of conversion of oligomeric bio42 to monomeric peptide and the selectivity of the single-site assay configuration for oligomers was provided by Sephadex G75 size exclusion chromatography (Figure 1). As oligomers dissociated, the void volume oligomer peak (>70 kDa) decreased in both the oligomerspecific (Figure 1, panel A) and total A β (Figure 1, panel B) profiles and the signal for total A β in the monomer region of the profile increased.

Dose-response curves (0 – 20 μ M) were generated for all six of the dihydroxy positional isomers, the three monohydroxy isomers, benzoic acid, and 3, 4, 5-trihydroxy benzoic acid. Figure 2 shows dose-response curves at 18 hours for the active compounds. The structures for the active compounds are shown in Table I. The 2, 3-, 2, 5-, and 3, 4- isomers of dihydroxybenzoic acid showed consistent bio42 oligomer dissociating activity at 16–18 hours to different degrees and with different kinetics. By contrast, 3, 4, 5-trihydroxybenzoate (gallic acid), the three monohydroxy benzoic acids (2-, 3-, and 4-hydroxybenzoic acid), and benzoic acid did not dissociate bio42 oligomers under these conditions. None of these compounds inhibited bio42 oligomer assembly at up to 20 μ M. The relative potencies of the active compounds were maintained throughout the time course of bio42 oligomer dissociation (Figure 3, Panel A), and the dissociation rate ($t_{1/2}$) was dependent on compound concentration (Figure 3, Panel B). The EC_{50} 's of the 2, 3- and 2, 5-DHBA compounds reached a minimum and plateaued after 10–12 hours, while the plateau with 3, 4-DHBA was reached after 4 hours (Figure 3, Panel C).

The effect of oligomer concentration on the potency (EC_{50}) of DHBA isomers (Figure 4) reveals a possible difference between DHBA isomers in their mechanism of dissociation. In all cases the concentration of DHBA isomer is in excess of the A β concentration (expressed as monomer). For the 2, 5- and 3, 4- isomers the difference is reflected in the lack of a significant shift in potency of the compounds as the oligomer (and total A β) concentration is increased. However, the 2,3-DHBA potency shows a steep dependence on oligomer concentration. At high oligomer concentration (~100 nM total A β), all of the compounds require a higher concentration of compound to dissociate 50% of oligomers, perhaps indicating a change in the way compounds interact with the oligomers.

A measure of A β oligomer and amyloid fibril structural integrity is their resistance to proteolytic degradation. Perturbation of oligomer structure by compound binding could expose protease-sensitive sites on bio42 oligomers or produce trypsin-sensitive intermediates. Monomeric peptide is readily fragmented by low concentrations of a variety of proteases. Treatment of oligomers with dissociating compounds at 10 μ M for 1 hour followed by trypsin digestion did not affect the sensitivity of bio42 oligomers to trypsin compared to the DMSO (no compound) control (data not shown). This suggests that treatment with the active DHBA isomers does not significantly perturb oligomer structure prior to dissociating the oligomers.

DHBA-like compounds were tested for their ability to antagonize bio42 oligomer dissociation by 2, 3-, 2, 5-, and 3, 4-DHBA. Non-oligomer-dissociating DHBA isomers, benzoic acid, and the monohydroxybenzoic acid isomers at 10 μ M failed to shift the dose-response curves of dissociation by the active DHBA isomers (data not shown). By themselves, non-dissociating compounds neither enhanced dissociation nor stabilized preformed oligomers over a range of compound concentrations, suggesting that the non-oligomer-dissociating compounds either do not bind to oligomers or bind at a different site. Thus, the orientation of the hydroxyl groups of the dihydrobenzoic acids is important in the dissociation mechanism.

Gallic acid stabilization of bio42 oligomers

By contrast to the non-oligomer-dissociating DHBA isomers, benzoic acid, and the monohydroxybenzoic acid isomers, gallic acid (3, 4, 5-trihydroxybenzoic acid) preserved the oligomer signal, blocking the basal (solvent control, no compound added) intrinsic rate of bio42 oligomer dissociation. Since gallic acid (20) and gallic acid-containing polyphenols such as (–)-epigallocatechin gallate (EGCG) have been reported to disrupt A β fibril structure (21) and remodel amyloidogenic polypeptides into unstructured non-toxic oligomeric species (22, 23) this was not an unexpected outcome. Consistent with the previously noted fibril remodeling, we confirmed that incubation of gallic acid with preformed A β (1–40) amyloid fibrils produced a time- and dose-dependent decrease in fibril-induced Thioflavine T fluorescence which was not due to gallic acid competition with the fluorophore. None of the other benzoic acid –related compounds, including the oligomer dissociators, had any effect on ThT fluorescence of fibrils even after several hours of incubation.

Exposure of preformed bio42 oligomers under the conditions of this assay (2.8 nM bio42 peptide in the presence of 0.1% Tween 20 for 16–18 hours at room temperature) to 10 μ M gallic acid did not lead to a decrease in the monomer or oligomer signal, nor was there a change in the apparent size distribution of oligomers due to the presence of gallic acid as assessed by chromatography on Sephadex G75, Sephacryl S-300, or Sepharose 6B. Apparent stabilization of oligomers is therefore not an artifact due to increased clumping of the peptide which was observed with fibrils (22).

Antagonism of 2, 3-, 2, 5- and 3, 4-DHBA bio42 oligomer dissociation by gallic acid

Gallic acid also stabilized bio42 oligomers against dissociation by 2, 3-, 2, 5-, and 3, 4-DHBA in a dose-dependent fashion. Increasing concentrations of gallic acid progressively shifted the concentration of dissociator required to achieve 50% oligomer dissociation to higher concentrations (Figure 5). The amount of gallic acid required to neutralize the effect of the different dissociators was similar ($\sim$ 5 μ M) even though the EC₅₀'s for the dissociators varies from 0.7 – 20 μ M. A similar concentration of gallic acid was required to stabilize the oligomer against intrinsic dissociation. This suggests that despite the structural similarity, the binding site for gallic acid that stabilizes bio42 oligomers against dissociation by DHBA derivatives is distinct from the site of action of the DHBA dissociating compounds.

Potential chemical modification of A β by DHBA derivatives

A potential mechanism for phenolic perturbation of A β fibrils and oligomers is chemical oxidative modification of peptide amino acid residues caused by redox cycling catalyzed by quinone adducts formed by some compounds like EGCG (22). The benzoic acid derivatives and several known redox-active phenolic compounds that inhibit A β fibril assembly were tested *in vitro* for their intrinsic ability at alkaline pH to reduce nitroblue tetrazolium in the presence of glycine as a source of reducing electrons to its intensely colored formazan (19). Figure 6 indicates the relative reactivity of 500 pmoles of each compound at 60 minutes of incubation. Only the benzoic acid derivatives with vicinal hydroxyls, 2, 3-, 3, 4-, and 3, 4, 5-substitution, generated significant signal. Several other polyphenols noted for their antioxidant activity were also redox active in this assay, including resveratrol, curcumin, and

nordihydroguaiaretic acid (Table II). The most active oligomer dissociation-inducing DHBA derivative is the 2, 5- isomer, yet it is <10% as redox active as the 2, 3- and 3, 4- isomers. Gallic acid (3, 4, 5- isomer) is highly redox active, yet it has no dissociating effect on preformed bio42 oligomers, although it does decrease ThT fluorescence of A β (1–40) fibrils. Hence, the potential for redox activity is not a prerequisite for oligomer dissociation, although it may be a contributing factor for some compounds.

2, 5-Dihydroxybenzoic acid dissociates oligomers but not by fragmentation

The production of small bio42 oligomers as reaction intermediates in the dissociation of the large >100 kDa bio42 oligomers by 2, 5-dihydroxybenzoic acid (gentisic acid) was investigated by size exclusion chromatography (stable intermediates) and by glutaraldehyde crosslinking (metastable intermediates). Superdex 75 analysis of dissociation reactions at different times following addition of either solvent control or 5 μ M 2, 5-DHBA failed to detect intermediates < 70 kDa, the exclusion limit for Superdex 75 (Fig. 7). Figure 7, Panel A shows the elution profile of bio42 with a characteristic oligomer peak in the column void volume (m.w. > 70 kDa, arrow) and a larger peak in the included volume of the column containing monomeric bio42 and comigrating dimer (due to the hydrodynamics of the unstructured peptide). Only two time points (0 and 5 hours) are shown for clarity. No intermediate sizes were observed at any time point. Integration of the bio42 content of the oligomer (fractions 37–50) and monomer (fractions 66–78) peaks provides an estimate of the quantity of the two species. Figure 7, Panel B shows that in the presence of 5 μ M 2, 5-DHBA the oligomer content decreases while the monomer content increases with time. The amount of dimer species that can be trapped by crosslinking from bio42 oligomers decreases with time of treatment (Figure 7, Panel C), and the decrease is dose-dependent (Figure 7, Panel D). The DMSO solvent controls show only a slow intrinsic dissociation of oligomers.

Discussion

A number of potential mechanisms could account for the dissociation of bio42 oligomers by the active DHBA compounds. Stabilization or sequestration of monomeric peptide by monomeric or micellar compound is unlikely since none of the DHBA isomers affect assembly of oligomers, even at high concentration. A mechanism involving the fission of the 100 – 600 kDa bio42 oligomer assemblies in the presence of DHBA dissociators is also unlikely as only oligomer and monomer (possibly dimer since they co-chromatograph by gel filtration) were observed by size exclusion chromatography. Intermediates < 70 kDa that were stable to chromatography were not detected, and glutaraldehyde crosslinking of treated oligomers revealed time- (Figure 7, Panel C) and concentration (Figure 7, Panel D) dependent decreases of dimeric species trapped from oligomers.

A more plausible explanation is that the DHBA isomers bind to and destabilize oligomers, increasing the rate at which A β monomers dissociate from the multimeric complex of peptides. The kinetics of the process also support this possibility as the time course of intrinsic oligomer dissociation (no compound present) is fit by a monoexponential function with a $t_{1/2}$ ~ 30 hours at 22 °C. In the presence of dissociating DHBA isomers the process

becomes bi-exponential with the second, faster rate dependent on the concentration of DHBA isomer (Figure 3).

Gentisic acid (2, 5-DHBA) is a simple phenolic compound, yet it is an effective dissociator of bio42 oligomers. It was a significantly more potent and rapid acting dissociator of bio42 oligomers than the 2, 3- and 3, 4- isomers, producing significant dissociation of preformed oligomers during the 2 hr binding to the NA-coated ELISA plate. The difference in slopes of the 2, 5-DHBA dissociation dose-response curves and the slopes of the $t_{1/2}$ with dose for the other two active DHBAs (Figure 3, Panel B) suggests a potential difference in mechanism of action. Both 2, 3- and 3, 4-DHBA were redox active *in vitro*, suggesting that the vicinal hydroxyls on the benzoic acid ring were prone to quinone formation. Since 2, 5-DHBA was only weakly redox active under the same conditions, quinone-mediated oxidative reactions could be one potential mechanism for oligomer dissociation, but not the only one, at least *in vitro*. By contrast, 3, 4, 5-trihydroxybenzoic acid, gallic acid, was not only strongly redox active, as was the more complex gallate-containing polyphenol EGCG. Neither agent dissociated oligomers. Gallic acid stabilized bio42 oligomers against dissociation by all three active DHBA dissociators. Since one of the reported properties of EGCG is to remodel fibrils into non-toxic oligomers, gallic acid may also convert toxic A β oligomers into non-toxic species. It thus appears that oligomer dissociation and detoxification may occur in different ways.

More detailed studies of compound interaction with oligomers will be required to fully elucidate the catalysis of A β oligomer disassembly. An advantage of the DHBA compounds is that they have relatively simple structures, yet are reasonably potent and soluble compared to the other complex polyhydroxy natural products that have been observed to have effects on A β fibril and oligomer structure. Their effect on biological oligomers will also be interesting since cell culture-produced biological A β oligomers and A β oligomers isolated from transgenic mice and from AD brain (24) are considerably more stable to disassembly than those formed from synthetic peptide.

Acknowledgments

This work was supported by AG028816.

ABBREVIATIONS

HFIP	1, 1, 1, 3, 3, 3-hexafluoroisopropanol
TFA	trifluoroacetic acid
PMSF	phenylmethylsulfonylfluoride

References

1. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A. 1998; 95:6448-6453. [PubMed: 9600986]

2. Hong HS, Maezawa I, Yao N, Xu B, Diaz-Avalos R, Rana S, Hua DH, Cheng RH, Lam KS, Jin LW. Combining the rapid MTT formazan exocytosis assay and the MC65 protection assay led to the discovery of carbazole analogs as small molecule inhibitors of Abeta oligomer-induced cytotoxicity. *Brain Res.* 2007; 1130:223–234. [PubMed: 17157826]
3. Glabe CG. Structural classification of toxic amyloid oligomers. *J Biol Chem.* 2008; 283:29639–29643. [PubMed: 18723507]
4. Malchiodi-Albedi F, Paradisi S, Matteucci A, Frank C, Diociaiuti M. Amyloid oligomer neurotoxicity, calcium dysregulation, and lipid rafts. *Int J Alzheimers Dis.* 2011; 2011:906964. [PubMed: 21331330]
5. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. *Nature.* 2002; 416:535–539. [PubMed: 11932745]
6. Selkoe DJ. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. *Behav Brain Res.* 2008; 192:106–113. [PubMed: 18359102]
7. Fa M, Orozco IJ, Francis YI, Saeed F, Gong Y, Arancio O. Preparation of oligomeric beta-amyloid 1–42 and induction of synaptic plasticity impairment on hippocampal slices. *J Vis Exp.* 2010
8. Ondrejcek T, Klyubin I, Hu NW, Barry AE, Cullen WK, Rowan MJ. Alzheimer's Disease Amyloid beta-Protein and Synaptic Function. *Neuromolecular Med.* 2009
9. De Felice FG, Vieira MN, Saraiva LM, Figueroa-Villar JD, Garcia-Abreu J, Liu R, Chang L, Klein WL, Ferreira ST. Targeting the neurotoxic species in Alzheimer's disease: inhibitors of Abeta oligomerization. *Faseb J.* 2004; 18:1366–1372. [PubMed: 15333579]
10. Necula M, Kaye R, Milton S, Glabe CG. Small-molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct. *J Biol Chem.* 2007; 282:10311–10324. [PubMed: 17284452]
11. Look GC, Jerecic J, Cherbavaz DB, Pray TR, Breach JC, Crosier WJ, Igoudin L, Hironaka CM, Lowe RM, McEntee M, Ruslim-Litrus L, Wu HM, Zhang S, Catalano SM, Goure WF, Summa D, Krafft GA. Discovery of ADDL--targeting small molecule drugs for Alzheimer's disease. *Curr Alzheimer Res.* 2007; 4:562–567. [PubMed: 18220523]
12. Kawasaki T, Onodera K, Kamijo S. Selection of Peptide inhibitors of soluble abeta(1–42) oligomer formation by phage display. *Bioscience, biotechnology, and biochemistry.* 2010; 74:2214–2219.
13. Reinke AA, Seh HY, Gestwicki JE. A chemical screening approach reveals that indole fluorescence is quenched by pre-fibrillar but not fibrillar amyloid-beta. *Bioorg Med Chem Lett.* 2009; 19:4952–4957. [PubMed: 19640715]
14. Walsh DM, Townsend M, Podlisny MB, Shankar GM, Fadeeva JV, Agnaf OE, Hartley DM, Selkoe DJ. Certain inhibitors of synthetic amyloid beta-peptide (Abeta) fibrillogenesis block oligomerization of natural Abeta and thereby rescue long-term potentiation. *J Neurosci.* 2005; 25:2455–2462. [PubMed: 15758153]
15. LeVine H 3rd. Biotin-avidin interaction-based screening assay for Alzheimer's beta-peptide oligomer inhibitors. *Anal Biochem.* 2006; 356:265–272. [PubMed: 16729955]
16. LeVine H 3rd, Ding Q, Walker JA, Voss RS, Augelli-Szafran CE. Clioquinol and other hydroxyquinoline derivatives inhibit Abeta(1–42) oligomer assembly. *Neurosci Lett.* 2009; 465:99–103. [PubMed: 19664688]
17. LeVine H 3rd. Alzheimer's beta-peptide oligomer formation at physiologic concentrations. *Anal Biochem.* 2004; 335:81–90. [PubMed: 15519574]
18. Murphy MP, Beckett TL, Ding Q, Patel E, Markesbery WR, St Clair DK, LeVine H 3rd, Keller JN. Abeta solubility and deposition during AD progression and in APPxPS-1 knock-in mice. *Neurobiol Dis.* 2007; 27:301–311. [PubMed: 17651976]
19. Fluckiger R, Paz MA, Gallop PM. Redox-cycling detection of dialyzable pyrroloquinoline quinone and quinoproteins. *Methods Enzymol.* 1995; 258:140–149. [PubMed: 8524146]
20. Di Giovanni S, Eleuteri S, Paleologou KE, Yin G, Zweckstetter M, Carrupt PA, Lashuel HA. Entacapone and tolcapone, two catechol O-methyltransferase inhibitors, block fibril formation of alpha-synuclein and beta-amyloid and protect against amyloid-induced toxicity. *J Biol Chem.* 2010; 285:14941–14954. [PubMed: 20150427]

21. Ladiwala AR, Dordick JS, Tessier PM. Aromatic small molecules remodel toxic soluble oligomers of amyloid {beta} through three independent pathways. *J Biol Chem.* 2010; 285:24228–24237. [PubMed: 20511235]
22. Ehrnhoefer DE, Bieschke J, Boeddrich A, Herbst M, Masino L, Lurz R, Engemann S, Pastore A, Wanker EE. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. *Nat Struct Mol Biol.* 2008; 15:558–566. [PubMed: 18511942]
23. Bieschke J, Russ J, Friedrich RP, Ehrnhoefer DE, Wobst H, Neugebauer K, Wanker EE. EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity. *Proc Natl Acad Sci U S A.* 2010; 107:7710–7715. [PubMed: 20385841]
24. Lesne S, Koh MT, Kotilinek L, Kaye R, Glabe CG, Yang A, Gallagher M, Ashe KH. A specific amyloid-beta protein assembly in the brain impairs memory. *Nature.* 2006; 440:352–357. [PubMed: 16541076]

Panel A.

Panel B.

Figure 1. 2, 5-Dihydroxybenzoic Acid Dissociates Bio42 Oligomers

Size exclusion chromatography of bio42 oligomers on Sephadex G75 (medium) in OFB + 0.1% Tween 20 before and after treatment of 16.8 nM bio42 oligomers (concentration as monomer) for 16 hours with: no compound (closed circle); 10 μM 2, 3-DHBA (closed inverted triangle); 10 μM 2, 5-DHBA (closed square); or 10 μM 3, 4-DHBA (closed diamond). Oligomers eluted between 2.25 and 2.75 ml; monomers eluted between 4 and 6 ml.

Panel A. Oligomer-specific assay- Biotinylated monomers and oligomers are captured in the wells of a Neutravidin (NA)-coated plate. Only oligomers are detected with SA-HRP because the single N-terminal biotin on monomeric peptide is bound by the NA. % no compounds = 1% DMSO solvent control.

Panel B. Total bio42 A β assay - Biotinylated monomers and oligomers are captured on an NA plate as with the oligomer-specific format in Panel A. Both oligomers and monomers are detected with an antibody (4G8, a.a. 17–24) to the middle of the A β peptide which is accessible in both NA-bound biotinylated oligomers and monomers.

Figure 2. Dose Response of DHBA Isomer Dissociation of Bio42 Oligomers

Preformed bio42 oligomers (2.8 nM) are incubated overnight at room temperature in the presence of the indicated concentrations of compounds and assayed for remaining oligomers as described in Methods.

Panel A.

Panel B.

Panel C.

Figure 3. Effect of DHBA Isomers on the Time Course of bio42 Oligomer Dissociation

Panel A. Time Course of Dissociation

The amount of oligomers remaining after incubation for different times with a range of concentrations of 2, 3-, 2, 5-, and 3, 4-DHBA were determined as described in Methods. The time point includes the 2 h incubation of oligomers with compound while binding to the NA plate. No compound (large open square); 2, 3-DHBA (closed inverted triangles); 2, 5-DHBA (closed squares); 3, 4-DHBA (closed diamonds). The smooth curves are calculated fits - no compound yields a single exponential decay; compounds produce double exponential decay.

Panel B. DHBA Concentration Dependence of the Half-time for Dissociation of bio42 oligomers

The half-times for dissociation plotted against concentration for the three dissociating DHBA compounds show similar slopes for 2, 3-DHBA (closed circles) and 2, 5-DHBA (closed inverted triangles), but is different for 3, 4-DHBA (closed squares). The open square is the half-time for the no compound vehicle (1% DMSO) control. The lines are linear least squares fit to the data for individual compounds.

Panel C. Time Dependence of DHBA EC₅₀ for bio42 Oligomer Dissociation

The apparent EC_{50} 's for dissociation decrease with incubation time to a plateau for each compound. 2, 3-DHBA (closed circles) and 2, 5-DHBA (closed inverted triangles) reach a minimum within 10–12 hours while 3, 4-DHBA (closed squares) is unchanged after 4 hours.

Figure 4. Bio42 Oligomer Concentration Dependence of Dissociating Compound Potency

The effectiveness (EC₅₀) of the three dissociating DHBA compounds was compared at different concentrations of bio42 oligomers. Oligomers were determined as described in Methods after appropriate dilution. 2, 3-DHBA (closed circles); 2, 5-DHBA (closed inverted triangles); 3, 4-DHBA (closed squares).

Panel A.

Panel B.

Panel C.

Figure 5. Gallic Acid (3, 4, 5-trihydroxybenzoic acid) Antagonizes bio42 Oligomer Dissociation by DHBA Isomers
 Preformed bio42 oligomers (2.8 nM) were incubated with a dose-response of 2, 3-DHBA (Panel A), 2, 5-DHBA (Panel B), and 3, 4-DHBA (Panel C) titrated at each DHBA concentration with 0 (closed circles); 0.625 μM (closed inverted triangles); 1.25 μM (closed squares); 2.5 μM (diamond); 5 μM (hexagon); and 10 μM (triangle) gallic acid, incubated for 16 hr and the oligomers determined as described in Methods. % no gallic acid = 1% DMSO solvent control.

Figure 6. Redox activity of phenolic compounds

The nitroblue tetrazolium reduction activity of benzoic acid derivatives and natural product polyphenols was measured as described in Methods. DHBA isomers as indicated; 3, 4, 5-THBA=3, 4, 5-trihydroxybenzoic acid (gallic acid); BA=benzoic acid; 2-HBA = 2-hydroxybenzoic acid; 3-HBA = 3-hydroxybenzoic acid; 4-HBA = 4-hydroxybenzoic acid; EGCG = (–)-epigallocatechin gallate; NDGA = nordihydroguaiaretic acid.

Panel A.

Panel B.

Panel C.

Panel D.

Figure 7. 2, 5-DHBA does not fragment bio42 oligomers into intermediate size species

Panel A. Superdex 75 profile of Aβ immunoreactivity treated for zero or 5 hours with 5 μM 2, 5-DHBA. After treating preformed bio42 oligomers (30 nM total bio42 with 2, 5-DHBA, the reaction mixture was chromatographed and fractions assayed for bio42 content as described in Methods. Closed circle and solid line = zero time; Open inverted triangle and dashed line = 5 hours. Arrow = column void volume and oligomer peak. Profiles were also run with samples treated for 2 and 8 hours.

Panel B. Treatment of bio42 oligomers with 2, 5-DHBA reduces the amount of oligomeric bio42 and increases the amount of monomeric bio42. Superdex 75 column profiles of bio42 content were run as in Panel A and the bio42 content of the oligomeric void volume (fractions 37–50) and monomer (fractions 66–78) summed to estimate the amount of oligomers and monomers

present after 0, 2, 5, and 8 hours of treatment with DMSO (open symbols and dashed lines) or 5 μ M 2, 5-DHBA (closed symbols and solid lines). The oligomer fraction is denoted by triangles and monomer fraction by circles.

Panel C. Glutaraldehyde crosslinking of bio42 oligomers treated with 2, 5-DHBA shows decreasing crosslinked dimer content with time. Oligomer samples from the time course of 2, 5-DHBA treatment were crosslinked with glutaraldehyde, electrophoresed, and dimer content quantified by SDS-PAGE as described in Methods. Open circles = DMSO; closed circles = 5 μ M 2, 5-DHBA.

Panel D. Glutaraldehyde crosslinking of bio42 oligomers treated with 2, 5-DHBA shows decreasing crosslinked dimer content with increasing 2, 5-DHBA concentration. Oligomer samples treated with a series of 2, 5-DHBA concentrations for 16 hours were crosslinked with glutaraldehyde, electrophoresed, and dimer content quantified by SDS-PAGE as described in Methods.

Table 1

Structures of Oligomer-Dissociating Dihydroxybenzoic Acid Isomers

Table 2

Structures of Natural Product Phenolics

[1]

[2]

[3]

[4]

[1] (-)-epigallocatechin gallate (EGCG)

[2] nordihydroguaiaretic acid (NDGA)

[3] resveratrol

[4] curcumin (enol-form)